Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 551

1.

One size doesn't fit all.

Lechner-Scott J, Giovannoni G, Hawkes C, Levy M, Waubant E.

Mult Scler Relat Disord. 2019 Jun;31:A1-A2. doi: 10.1016/j.msard.2019.04.034. Epub 2019 Apr 30. No abstract available.

PMID:
31159999
2.

Screening performance of abbreviated versions of the UPSIT smell test.

Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE, Noyce AJ.

J Neurol. 2019 May 3. doi: 10.1007/s00415-019-09340-x. [Epub ahead of print]

PMID:
31053960
3.

Survival: the ultimate long-term outcome in multiple sclerosis.

Giovannoni G.

Brain. 2019 May 1;142(5):1166-1167. doi: 10.1093/brain/awz101. No abstract available.

PMID:
31032846
4.

Three suggestions to decrease the financial burden of MS treatments.

Waubant E, Giovannoni G, Hawkes C, Lechner-Scott J, Levy M.

Mult Scler Relat Disord. 2019 May;30:A1. doi: 10.1016/j.msard.2019.03.023. No abstract available.

PMID:
30987755
5.

Chronic-relapsing varicella zoster meningitis - Successfully treated with varicella vaccine.

Gaiottino J, Giovannoni G, Breuer J, Tang JW.

J Infect. 2019 Jul;79(1):61-74. doi: 10.1016/j.jinf.2019.04.009. Epub 2019 Apr 10. No abstract available.

PMID:
30980839
6.

Visibility and representation of women in multiple sclerosis research.

Thomson A, Horne R, Chung C, Marta M, Giovannoni G, Palace J, Dobson R.

Neurology. 2019 Apr 9;92(15):713-719. doi: 10.1212/WNL.0000000000007276. Epub 2019 Mar 20. Review.

7.

Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease.

Levy M, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E.

Mult Scler Relat Disord. 2019 Apr;29:A1-A2. doi: 10.1016/j.msard.2019.03.007. No abstract available.

PMID:
30885376
8.

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.

Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.

Mult Scler Relat Disord. 2019 Apr;29:168-174. doi: 10.1016/j.msard.2019.01.038. Epub 2019 Jan 24.

9.

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.

Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.

10.

Multiple Sclerosis and Vitamin D - Caviar or a Dog's Dinner?

Hawkes C, Giovannoni G, Lechner-Scott J, Levy M, Waubant E.

Mult Scler Relat Disord. 2019 Feb;28:A1-A2. doi: 10.1016/j.msard.2019.02.015. No abstract available.

PMID:
30823982
11.

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.

Axelsson M, Dubuisson N, Novakova L, Malmeström C, Giovannoni G, Lycke J, Gnanapavan S.

Acta Neurol Scand. 2019 May;139(5):422-427. doi: 10.1111/ane.13069. Epub 2019 Mar 5.

PMID:
30657162
12.

Should our treatment target in MS include the intrathecal plasma cell response?

Giovannoni G, Hawkes C, Levy M, Lechner-Scott J, Waubant E.

Mult Scler Relat Disord. 2019 Jan;27:A1-A2. doi: 10.1016/j.msard.2018.12.039. No abstract available.

PMID:
30642567
13.

UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines.

Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA.

Pract Neurol. 2019 Apr;19(2):106-114. doi: 10.1136/practneurol-2018-002060. Epub 2019 Jan 5. Review.

PMID:
30612100
14.

Is the 'MS establishment' biased; the case for addressing gender inequality in the field of MS?

Giovannoni G.

Mult Scler Relat Disord. 2019 Feb;28:153-154. doi: 10.1016/j.msard.2018.12.020. Epub 2018 Dec 20. No abstract available.

PMID:
30594816
15.

Vaccines and disease-modifying treatments.

Waubant E, Giovannoni G, Hawkes C, Levy M.

Mult Scler Relat Disord. 2018 Nov;26:A1-A2. doi: 10.1016/j.msard.2018.10.017. Epub 2018 Oct 24. No abstract available.

PMID:
30573174
16.

Social capital: Implications for neurology.

Reyes S, Giovannoni G, Thomson A.

Brain Behav. 2019 Jan;9(1):e01169. doi: 10.1002/brb3.1169. Epub 2018 Dec 8. Review.

17.

Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP, Marta M, Gnanapavan S, Espasandin M, Mathews J, Giovannoni G, Baker D, Schmierer K.

Mult Scler Relat Disord. 2019 Jan;27:247-253. doi: 10.1016/j.msard.2018.11.001. Epub 2018 Nov 2.

PMID:
30419510
18.

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.

Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G.

Mult Scler. 2018 Dec;24(14):1862-1870. doi: 10.1177/1352458518808189. Epub 2018 Nov 12.

19.

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier.

Yeandle D, Rieckmann P, Giovannoni G, Alexandri N, Langdon D.

Neurol Ther. 2018 Dec;7(2):179-187. doi: 10.1007/s40120-018-0118-8. Epub 2018 Nov 9.

20.

The unintended consequences of NICE.

Giovannoni G.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):247-248. doi: 10.1136/jnnp-2018-318866. Epub 2018 Nov 2. No abstract available.

PMID:
30389780
21.

Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica.

Levy M, Giovannoni G, Hawkes C, Waubant E.

Mult Scler Relat Disord. 2018 Oct;25:A1-A2. doi: 10.1016/j.msard.2018.09.027. No abstract available.

PMID:
30384960
22.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
23.

The Multiple Sclerosis Care Unit.

Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G.

Mult Scler. 2019 Apr;25(5):627-636. doi: 10.1177/1352458518807082. Epub 2018 Oct 23.

24.

Learning ability correlates with brain atrophy and disability progression in RRMS.

Sormani MP, De Stefano N, Giovannoni G, Langdon D, Piani-Meier D, Haering DA, Kappos L, Tomic D.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):38-43. doi: 10.1136/jnnp-2018-319129. Epub 2018 Oct 15.

25.

Inclusion criteria used in trials of people with progressive multiple sclerosis.

Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G.

Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769. [Epub ahead of print] No abstract available.

PMID:
30318994
26.

Multiple sclerosis - a review.

Dobson R, Giovannoni G.

Eur J Neurol. 2019 Jan;26(1):27-40. doi: 10.1111/ene.13819. Epub 2018 Nov 18. Review.

PMID:
30300457
27.

e-Health and multiple sclerosis: An update.

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S.

Mult Scler. 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19.

PMID:
30231004
28.

Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis.

Baker D, Pryce G, Amor S, Giovannoni G, Schmierer K.

Brain. 2018 Oct 1;141(10):2834-2847. doi: 10.1093/brain/awy239.

PMID:
30212896
29.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

30.

Editors' Welcome.

Hawkes CH, Giovannoni G, Levy M, Waubant E.

Mult Scler Relat Disord. 2018 Aug;24:A1-A2. doi: 10.1016/j.msard.2018.08.010. No abstract available.

PMID:
30190056
31.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

32.

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L.

Ann Neurol. 2018 Oct;84(4):527-536. doi: 10.1002/ana.25313.

33.

Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss.

Gushchina S, Pryce G, Yip PK, Wu D, Pallier P, Giovannoni G, Baker D, Bo X.

Glia. 2018 Oct;66(10):2108-2125. doi: 10.1002/glia.23464. Epub 2018 Aug 25.

PMID:
30144320
34.

Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts.

Holden DW, Gold J, Hawkes CH, Giovannoni G, Saxton JM, Carter A, Sharrack B.

Mult Scler Relat Disord. 2018 Oct;25:197-199. doi: 10.1016/j.msard.2018.07.041. Epub 2018 Jul 27.

PMID:
30099206
35.

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G, Turner BP, Marta M, Mathews J, Giovannoni G, Baker D, Schmierer K.

Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783767. doi: 10.1177/2055217318783767. eCollection 2018 Apr-Jun.

36.

Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial.

Casha S, Rice T, Stirling DP, Silva C, Gnanapavan S, Giovannoni G, Hurlbert RJ, Yong VW.

J Neurotrauma. 2018 Aug 15;35(16):1918-1928. doi: 10.1089/neu.2018.5899.

PMID:
30074872
37.

Women on multiple sclerosis clinical trial steering committees.

Moneim J, Coles A, Giovannoni G, Horne R, Carr O.

Ann Neurol. 2018 Aug;84(2):329-330. doi: 10.1002/ana.25306. Epub 2018 Sep 9. No abstract available.

PMID:
30063257
38.

Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein?

Giovannoni G.

Brain. 2018 Aug 1;141(8):2235-2237. doi: 10.1093/brain/awy200. No abstract available.

PMID:
30060019
39.

Is cognitive impairment in multiple sclerosis reversible?

Giovannoni G, Hawkes C, Levy M, Waubant E.

Mult Scler Relat Disord. 2018 Jul;23:A1. doi: 10.1016/j.msard.2018.07.007. No abstract available.

PMID:
30049507
40.

Cladribine: mechanisms and mysteries in multiple sclerosis.

Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-1271. doi: 10.1136/jnnp-2017-317411. Epub 2018 Jul 10.

PMID:
29991490
41.

A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.

Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L, Adiutori R, MacManus D, Yousry T, Schmierer K, Turner B, Giovannoni G.

Mult Scler Relat Disord. 2018 Aug;24:123-128. doi: 10.1016/j.msard.2018.06.002. Epub 2018 Jun 28.

PMID:
29990894
42.

Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine.

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D, Gnanapavan S, Schmierer K.

Mult Scler Relat Disord. 2018 Aug;24:20-27. doi: 10.1016/j.msard.2018.05.010. Epub 2018 Jun 1.

PMID:
29860198
43.

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Marshall I, Thrippleton MJ, Bastin ME, Mollison D, Dickie DA, Chappell FM, Semple SIK, Cooper A, Pavitt S, Giovannoni G, Wheeler-Kingshott CAMG, Solanky BS, Weir CJ, Stallard N, Hawkins C, Sharrack B, Chataway J, Connick P, Chandran S; MS-SMART Trialists.

J Neurol. 2018 Aug;265(8):1795-1802. doi: 10.1007/s00415-018-8903-y. Epub 2018 May 30.

44.

Diagnosing and caring for MS in Haiti.

Waubant E, Berkowitz A, Giovannoni G, Hawkes C, Levy M.

Mult Scler Relat Disord. 2018 May;22:A1-A2. doi: 10.1016/j.msard.2018.05.009. No abstract available.

PMID:
29807822
45.

No Evident Disease Activity-More Than a Risky Ambition?

Jacobs BM, Giovannoni G, Schmierer K.

JAMA Neurol. 2018 Jul 1;75(7):781-782. doi: 10.1001/jamaneurol.2018.0829. No abstract available.

PMID:
29800951
46.

Editors' Welcome: Pregnancy and progressive multifocal leukoencephalopathy.

Levy M, Giovannoni G, Hawkes C, Waubant E.

Mult Scler Relat Disord. 2018 Apr;21:A1-A2. doi: 10.1016/j.msard.2018.03.016. No abstract available.

PMID:
29724377
47.

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.

Mult Scler. 2019 May;25(6):819-827. doi: 10.1177/1352458518771875. Epub 2018 May 2.

48.

Complexity of MS management in the current treatment era.

Chitnis T, Giovannoni G, Trojano M.

Neurology. 2018 Apr 24;90(17):761-762. doi: 10.1212/WNL.0000000000005399. No abstract available.

PMID:
29686111
49.

Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm.

Giovannoni G.

Curr Opin Neurol. 2018 Jun;31(3):233-243. doi: 10.1097/WCO.0000000000000561. Review.

PMID:
29634596
50.

Are the high-costs of MS disease-modifying therapies justified?

Giovannoni G, Hawkes C, Levy M, Waubant E.

Mult Scler Relat Disord. 2018 Feb;20:A3-A5. doi: 10.1016/j.msard.2018.02.018. No abstract available.

PMID:
29579631

Supplemental Content

Loading ...
Support Center